Disclosures for "Analysis of Potential Biomarkers and Clinical Scale in Atypical CLN2 Enzyme Replacement Therapy Patients"
-
Ms. Villars has nothing to disclose.
-
Mrs. Stewart has nothing to disclose.
-
Ms. Fote has nothing to disclose.
-
The institution of Dr. Olaya has received research support from NIH.
-
Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zevra Therapeutics. Dr. Wang has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Denali Therapeutics. Dr. Wang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Green Cross Therapeutics. Dr. Wang has stock in Biomarin Pharmaceuticals. The institution of Dr. Wang has received research support from Biomarin Pharmaceuticals.